Detail
| LncRNA Name | HCP5 |
| Synonyms | D6S2650E, P5-1 |
| Region | GRCh38_6:31400702-31477506 Sequence |
| Ensembl | ENSG00000206337 |
| RefSeq | NR_040662 |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | follicular thyroid carcinoma |
| ICD-0-3 | C73 M8330/3 |
| Methods | RNA-seq, qPCR, RNAi etc. |
| Sample | cell lines (FTC-133, FTC-238, Nthy-ori 3-1, HEK293T, HUVECs), FTC tissues |
| Expression Pattern | up-regulated |
| Function Description | Overexpression of HCP5 can promote the proliferation,migration,invasiveness and angiogenic ability of FTC cells.HCP5 and alpha-2,6-sialyltransferase 2 (ST6GAL2) were co-expressed in FTC.We hypothesised that ST6GAL2 may be regulated by HCP5, which would in turn mediate the activity of FTC cells.HCP5 functions as a competing endogenous RNA (ceRNA) and acts as a sponge for miR-22-3p, miR-186-5p and miR-216a-5p, which activates ST6GAL2. |
| Pubmed ID | 29515098 |
| Year | 2018 |
| Title | LncRNA HCP5 promotes follicular thyroid carcinoma progression via miRNAs sponge. |
| External Links |
| Links for HCP5 | GenBank HGNC lncrnadb Noncode |
| Links for follicular thyroid carcinoma | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.